Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
testing
OMRF Genomics Center earns CAP accreditation
OMRF’s Clinical Genomics Center will now be able to offer services to clinicians.
Eisai, OMRF enter autoimmune disease research collaboration
The project is focused on lupus, which affects up to 1.5 million Americans.
Trial participants are unsung heroes of research
Patient volunteers like Phyllis Smith are vital to the drug trial process.